Join us October 5-6 at the AANS/CNS Joint Tumor Section's 2018 Tumor Satellite Symposium, held at the Marriott Marquis Houston. Visit our booth during the exhibit breaks, and don't miss our special ZEISS-sponsored lunch symposium.
Friday, October 5, Briargrove A/B
12:10 - 1:10 PM
Christopher P. Cifarelli, MD, PhD
Director, Gamma Knife Radiosurgery
Assistant Professor of Neurosurgery, West Virginia University
Peter Nakaji, MD
Professor of Neurosurgery, Barrow Neurological Institute, Arizona
Join us throughout the exhibit hours for insightful demonstrations of our platforms, designed to suit the high demands of neurosurgery. Experience the newest technology in neurosurgical visualization, including KINEVO® 900, The Robotic Visualization System™
- Surgeon-Controlled Robotics
- QEVO® from ZEISS - The Micro-Inspection Tool
- Digital Hybrid Visualization
Hear firsthand experiences from your peers at our Lunch Symosium during the CNS Annual Meeting.
Monday, October 8, Exhibit Hall Lunch Theater B
12:15 - 1:45 PM
Joshua B. Bederson, MD
Professor and System Chair
Department of Neurosurgery at Mount Sinai Health System, New York
Evgenii Belykh, MD
Department of Neurosurgery
Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Arizona
Bookmark the ZEISS CNS website and return often for updates.
Tell us more about yourself and we’ll keep you informed as we add new events and information.
In accordance with the Open Payments (“Sunshine”) provisions of the Patient Protection and Affordable Care Act (and similar state laws), the value of this lunch is subject to public disclosure, and therefore will be reported in compliance with all applicable laws.
This event will be videotaped, photographed, and/or audiotaped. The videos, photographs, and/or audio recording may appear on the ZEISS website, proprietary apps, marketing materials in various print or digital formats, and/or social platforms.
The discussion may include information on products and features that are a work in progress, may require FDA 510(k) clearance and are subject to change. Future availability cannot be guaranteed.
These sessions may include discussion of a drug that is not approved in the United States as well as drug applications and device applications that are not cleared in the United States.